30 citations,
July 2019 in “Endocrinology” Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.
20 citations,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
12 citations,
January 2019 in “Journal of Endocrinology” Baicalin may help reduce excessive male hormone levels in PCOS.
8 citations,
December 2022 in “International journal of molecular sciences” Mice without the enzyme HSD17B3 still produce normal testosterone, suggesting they have different ways to make it compared to humans.
7 citations,
May 2019 in “Journal of the Formosan Medical Association” HSD3B1 gene variant and being overweight linked to hair loss in women with polycystic ovary syndrome.
1 citations,
January 2017 in “Tohoku journal of experimental medicine” A woman's mature cystic teratoma caused her virilization by producing testosterone.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” HSD11b1 affects skin nerves and increases non-histaminergic itch.
September 2018 in “Fertility and Sterility” The HSD3B1 variant increases hair loss risk in overweight women with PCOS.
45 citations,
September 1998 in “Journal of Investigative Dermatology” The enzyme 17β-HSD type 2 mainly performs oxidation in human sebaceous glands, which may help protect against acne.
May 2021 in “Journal of the Endocrine Society” A woman's hair loss and other symptoms were due to a rare hormone deficiency treatable with steroids.
18 citations,
December 2010 in “The Journal of Steroid Biochemistry and Molecular Biology” Increased HSD11B1 enzyme expression is linked to higher body fat and insulin resistance.
10 citations,
January 2019 in “Archives of Endocrinology and Metabolism” Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.
69 citations,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
28 citations,
August 2003 in “Steroids” Hirsute women have lower type 2 17β-HSD enzyme levels, which improve with treatment.
3 citations,
January 2017 in “Yonsei Medical Journal” Blocking 11β-HSD1 can lessen the harmful effects of glucocorticoids on hair growth cells.
Blocking 11β-HSD1 reduces stress hormone damage in hair growth cells.
43 citations,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
100 citations,
July 2004 in “The Journal of Sexual Medicine” Hormones like estrogen, testosterone, progesterone, and prolactin play complex roles in female sexual function, with testosterone potentially improving sexual desire, arousal, and satisfaction. However, more research is needed to establish safe and effective hormone treatments for female sexual dysfunction.
75 citations,
February 2016 in “The Journal of Sexual Medicine” Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.
70 citations,
April 2014 in “Annales d'endocrinologie” New genes and pathways are important for testosterone production and male sexual development.
66 citations,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
56 citations,
November 2007 in “Molecular and cellular endocrinology” Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
30 citations,
April 2021 in “The Journal of Sexual Medicine” Testosterone therapy can help postmenopausal women with low sexual desire if monitored carefully.
28 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.
26 citations,
January 2020 in “Przegląd Menopauzalny” Menopausal women have higher androgen levels, which can cause symptoms like facial hair growth and low sexual desire.
20 citations,
April 2021 in “Journal of Womens Health” Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.
13 citations,
November 2012 in “PubMed” 5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
11 citations,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
7 citations,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
3 citations,
October 2022 in “International Journal of Impotence Research” Testosterone Replacement Therapy can improve sexual health in postmenopausal women with low sexual desire, but more research is needed on its long-term effects.